L. Boulet

Publications285
h-index55
Citations15,972
Highly Influential Citations590
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. O'Byrne
  • 632 Publications, 43,099 Citations
  • J. Bousquet
  • 841 Publications, 57,348 Citations
  • G. Gauvreau
  • 233 Publications, 6,374 Citations
  • I. Pavord
  • 548 Publications, 39,903 Citations
  • Publications
  • Influence
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *
J. Bousquet, N. Khaltaev, A. A. Cruz, J. Denburg, W. J. Fokkens, A. Togias, T. Zuberbier, C. E. Baena-Cagnani, G. W. Canonica, C. van Weel, I. Agache, N. A t-Khaled, C. Bachert, M. S. Blaiss, S.… Expand
  • 2,883
  • 165
  • PDF
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.
BACKGROUND The assessment of asthma control is pivotal to the evaluation of treatment response in individuals and in clinical trials. Previously, asthma control, severity, and exacerbations were… Expand
  • 1,355
  • 51
  • PDF
Global asthma prevalence in adults: findings from the cross-sectional world health survey
BackgroundAsthma is a major cause of disability, health resource utilization and poor quality of life world-wide. We set out to generate estimates of the global burden of asthma in adults, which may… Expand
  • 853
  • 46
  • PDF
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines.
Recognition of the importance of cough in clinical medicine was the impetus for the original evidence-based consensus panel report on “Managing Cough as a Defense Mechanism and as a Symptom,”… Expand
  • 596
  • 23
  • PDF
A summary of the new GINA strategy: a roadmap to asthma control
Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and annually updated a global strategy for asthma management and prevention that has formed the basis for many… Expand
  • 542
  • 21
Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
RATIONALE Eosinophilic asthma is a phenotype of asthma characterized by the persistence of eosinophils in the airways. IL-5 is involved in the activation and survival of eosinophils. OBJECTIVES To… Expand
  • 438
  • 12
Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR
Background:  Anti‐IgE therapy could be particularly beneficial for patients with concomitant disease as it targets a common factor in both diseases. The aim of this study was to evaluate the efficacy… Expand
  • 332
  • 11
  • PDF
Asthma, airway inflammation and epithelial damage in swimmers and cold-air athletes
Endurance athletes show an increased prevalence of airway hyperresponsiveness. The aim of the present study was to evaluate the long-term effects of training on airway responsiveness, inflammation… Expand
  • 152
  • 11
Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation.
Smoking may influence the type of airway inflammation observed in asthma and its response to therapy. More studies are needed on how smoking-induced changes in lung function/structure and airway… Expand
  • 195
  • 9
  • PDF
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.
BACKGROUND Thymic stromal lymphopoietin (TSLP) is an epithelial-cell-derived cytokine that may be important in initiating allergic inflammation. AMG 157 is a human anti-TSLP monoclonal immunoglobulin… Expand
  • 541
  • 8